EndoDNA Launches BIOS, an Adaptive Clinical Decision-Support Platform That Turns Genetic Data Into Living Intelligence for Precision Medicine
核心洞察
EndoDNA (搜索) launched BIOS (搜索), a patented clinical decision-support platform that replaces static DNA reports with an adaptive, longitudinal dashboard for licensed healthcare practitioners.
BIOS (搜索) analyzes approximately 1 million validated genetic variants across 21 pathway systems and 214 curated pathways, mapping data across hormone metabolism, inflammation, and neurotransmitter regulation.
The platform integrates four connected memory networks — World, Experience, Opinion, and Observation — to generate evolving, personalized clinical insights rather than one-time interpretations.
EndoDNA (搜索), a precision health intelligence company based in Studio City, California, today announced the launch of BIOS (搜索) (Biomedical Reasoning and Adaptive Inference Network), a patented, intelligent clinical decision-support platform designed to replace static, one-time genetic reports with an adaptive, continuously updating dashboard for licensed healthcare practitioners. The platform, which succeeds the company's legacy interpretation engine myDNALive, is now immediately available to clinicians practicing in functional, integrative, regenerative, hormone-optimization, and longevity medicine.
"For years, clinicians have had access to more biological data than ever before, but very few tools to help them actually apply it," said Len May, Founder and CEO of EndoDNA (搜索). "Most genetic platforms stop at information. BIOS (搜索) was built to answer the question clinicians are really asking: 'Now what?' It transforms complex biology into structured clinical insight that evolves alongside the patient; helping providers move from interpretation to action with greater clarity and consistency."
Built Around Biological Pathways, Not Isolated SNPs
Unlike consumer DNA platforms or general-purpose AI tools, BIOS (搜索) is architected around interconnected biological pathways rather than isolated single-nucleotide polymorphism (SNP) interpretation. The platform maps genomic data across vital systems including hormone metabolism and metabolic signaling, inflammation and stress response, and neurotransmitter regulation and cognitive function. In total, BIOS analyzes approximately 1 million validated variants across 21 pathway systems, with 214 pathways actively curated for real-time clinical decision support.
Four Connected Memory Networks
BIOS (搜索) does not evaluate single data points in isolation. Instead, it reasons across four connected memory networks that collectively build a comprehensive, longitudinal picture of each patient. The World network integrates population-level genomic evidence from sources such as biobanks, the Clinical Pharmacogenetics Implementation Consortium (CPIC), and PharmGKB. The Experience network draws on aggregated practitioner case history to surface what has worked for similar patients. The Opinion network captures a practitioner's own notes and overrides to refine and personalize recommendations. Finally, the Observation network tracks patient-reported outcomes and biomarker trends over time.
Through a single, HIPAA-compliant dashboard, licensed practitioners can order DNA tests, generate unlimited specialized reports from existing genotype files, integrate biomarker and lab data, analyze pharmacogenomic interactions, and query patient genomic data using natural-language search. Available report categories include Female and Male Regenerative Health, NeuroDNA Cognitive & Neurological Health, Nutrigenomics & Metabolic Pathway Analysis, Endocannabinoid System (ECS) Panels, and Hormone Optimization & Longevity Pathways.
Clinical Validation and Patented Innovation
Since its founding, EndoDNA (搜索) has served more than 10,000 patients across more than 9 countries through CAP/CLIA-accredited laboratory partners. The company employs Illumina next-generation sequencing to deliver a 99.6% genotyping accuracy rate. EndoDNA holds more than 10 issued and pending patents, including the industry's only patented methodology for genotyping the endocannabinoid system (ECS), as well as a patented machine-learning methodology for predicting efficacy from genetic and biometric data.
"For years, clinicians have had access to more data than they could reasonably interpret. What has been missing is a reliable way to translate that information into clinical action," said Dr. Allen Lawrence, MA, MD, PhD. "EndoDNA (搜索) and BIOS (搜索) help solve that problem by transforming complex genomic and biological inputs into organized, actionable intelligence. The result is a more scalable precision medicine model; one that allows providers to make better-informed decisions, improve patient engagement, and deliver truly personalized care more efficiently."
BIOS (搜索) is available immediately to licensed healthcare practitioners as a clinical decision-support and research-use platform, marking a significant step toward integrating living, evolving genomic intelligence into routine precision medicine workflows.